Summary:
A 52-week treatment, randomized, double blind, placebo controlled, with open label tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with Chronic Obstructive Pulmonary Disease (COPD)
Qualified Participants Must:
• Be 40 years of age or older
•
Have stable moderate to severe COPD
Qualified Participants May Receive:
Free medications and reimbursement for time and travel.